BSTC has been the topic of several other reports. Zacks Investment Research lowered shares of BioSpecifics Technologies from a hold rating to a sell rating in a research report on Wednesday, August 14th. HC Wainwright reiterated a buy rating and set a $90.00 target price (up from $85.00) on shares of BioSpecifics Technologies in a research report on Monday, August 12th. Finally, ValuEngine lowered shares of BioSpecifics Technologies from a hold rating to a sell rating in a research report on Thursday, August 1st.
NASDAQ BSTC opened at $58.17 on Friday. The firm has a market capitalization of $424.63 million, a price-to-earnings ratio of 21.31 and a beta of 1.17. The company’s fifty day moving average is $56.76 and its two-hundred day moving average is $61.80. BioSpecifics Technologies has a 52-week low of $52.03 and a 52-week high of $73.31.
BioSpecifics Technologies (NASDAQ:BSTC) last posted its quarterly earnings results on Friday, August 9th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.15. The company had revenue of $8.85 million for the quarter, compared to analyst estimates of $8.98 million. BioSpecifics Technologies had a net margin of 63.06% and a return on equity of 21.97%. Sell-side analysts forecast that BioSpecifics Technologies will post 3.17 earnings per share for the current year.
In other news, Director Toby Wegman sold 1,100 shares of BioSpecifics Technologies stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $55.23, for a total transaction of $60,753.00. Following the sale, the director now directly owns 1,890 shares in the company, valued at approximately $104,384.70. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 16.39% of the stock is currently owned by insiders.
Institutional investors have recently modified their holdings of the company. Advisor Group Inc. boosted its position in shares of BioSpecifics Technologies by 94.2% during the 2nd quarter. Advisor Group Inc. now owns 734 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 356 shares in the last quarter. Advantage Investment Management LLC boosted its position in shares of BioSpecifics Technologies by 40.9% during the 2nd quarter. Advantage Investment Management LLC now owns 957 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 278 shares in the last quarter. BNP Paribas Arbitrage SA boosted its position in shares of BioSpecifics Technologies by 60,150.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 1,205 shares of the biopharmaceutical company’s stock valued at $75,000 after acquiring an additional 1,203 shares in the last quarter. Shaker Investments LLC OH acquired a new stake in shares of BioSpecifics Technologies during the 2nd quarter valued at about $205,000. Finally, Victory Capital Management Inc. acquired a new stake in shares of BioSpecifics Technologies during the 1st quarter valued at about $248,000. Institutional investors and hedge funds own 59.16% of the company’s stock.
About BioSpecifics Technologies
BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brands.
Featured Story: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.